NCT03707730View on ClinicalTrials.gov

A Randomized, Double-Blind, Placebo Controlled, Crossover Trial to Evaluate Safety and Efficacy of AGY in Celiac Disease

PHASE2CompletedINTERVENTIONAL

Enrollment

161

Participants

Timeline

Start Date

October 29, 2019

Primary Completion Date

December 31, 2023

Study Completion Date

December 31, 2023

Conditions

Celiac Disease

Interventions

DIETARY_SUPPLEMENT

AGY

oral AGY taken prior to meals

OTHER

placebo

oral placebo taken prior to meals

Trial Locations (2)

T6G 1C9

University of Alberta, Edmonton

R2H 2A6

St Boniface Hospital, Winnipeg

All Listed Sponsors

collaborator

Vetanda Group Ltd

UNKNOWN

lead

Igy Inc.

INDUSTRY

NCT03707730 - A Randomized, Double-Blind, Placebo Controlled, Crossover Trial to Evaluate Safety and Efficacy of AGY in Celiac Disease | Biotech Hunter | Biotech Hunter